Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 23;10(8):1864.
doi: 10.3390/cells10081864.

TRIM22. A Multitasking Antiviral Factor

Affiliations
Review

TRIM22. A Multitasking Antiviral Factor

Isabel Pagani et al. Cells. .

Abstract

Viral invasion of target cells triggers an immediate intracellular host defense system aimed at preventing further propagation of the virus. Viral genomes or early products of viral replication are sensed by a number of pattern recognition receptors, leading to the synthesis and production of type I interferons (IFNs) that, in turn, activate a cascade of IFN-stimulated genes (ISGs) with antiviral functions. Among these, several members of the tripartite motif (TRIM) family are antiviral executors. This article will focus, in particular, on TRIM22 as an example of a multitarget antiviral member of the TRIM family. The antiviral activities of TRIM22 against different DNA and RNA viruses, particularly human immunodeficiency virus type 1 (HIV-1) and influenza A virus (IAV), will be discussed. TRIM22 restriction of virus replication can involve either direct interaction of TRIM22 E3 ubiquitin ligase activity with viral proteins, or indirect protein-protein interactions resulting in control of viral gene transcription, but also epigenetic effects exerted at the chromatin level.

Keywords: DNA and RNA viruses; HIV-1; TRIM22; influenza A virus; interferons.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Structural organization of the HIV-1 promoter. HIV-1 transcription starts at the promoter region in the 5′ LTR. Processive HIV-1 transcription is driven by the Tat protein that recruits the p-TEFb complex to the TAR RNA. pTEFb promotes the phosphorylation of the RNA Pol II, enabling the elongation of the viral transcripts. Upstream of the initiation of transcription (+1), three Sp1 and two NF-kB binding sites control the levels of basal transcription and response to inflammatory signals, respectively. (B) TRIM22 inhibits HIV-1 basal transcription by preventing Sp1 binding to the HIV-1 promoter, thus contributing to the maintenance of latent HIV-1 infection.
Figure 2
Figure 2
Evolution from pandemic to seasonal IAV has shaped TRIM22 restriction. Pandemic viruses are resistant to TRIM22 inhibition as their NP is endowed with four arginine (R) residues that progressively mutate into lysine (K) residues, becoming the target of the U3 ubiquitin ligase activity of TRIM22. The transition of R into K is dependent on viral polymerase errors that generate viral quasispecies either characterized by one, two, three or four K residues. However, a bottleneck of transmission favors the emergence of an IAV NP susceptible to TRIM22 restriction. This phenomenon is likely related to the general rule of viral evolution which endows the virus with the ability to become more transmissible and less pathogenic.

References

    1. Cao X. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat. Rev. Immunol. 2016;16:35–50. doi: 10.1038/nri.2015.8. - DOI - PubMed
    1. Shows T.B., Sakaguchi A.Y., Naylor S.L., Goedell D.V., Lawn R.M. Clustering of leukocyte and fibroblast interferon genes of human chromosome 9. Science. 1982;218:373–374. doi: 10.1126/science.6181564. - DOI - PubMed
    1. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004;202:8–32. doi: 10.1111/j.0105-2896.2004.00204.x. - DOI - PubMed
    1. Stark G.R., Darnell J.E., Jr. The JAK-STAT pathway at twenty. Immunity. 2012;36:503–514. doi: 10.1016/j.immuni.2012.03.013. - DOI - PMC - PubMed
    1. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481–485. doi: 10.1038/nature09907. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances